Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cencora ( (COR) ) has shared an announcement.
On May 7, 2025, Cencora announced its fiscal 2025 second-quarter results, reporting a 10.3% year-over-year revenue increase to $75.5 billion. The company also raised its adjusted diluted EPS guidance for fiscal 2025, reflecting strong performance driven by its U.S. Healthcare Solutions segment and strategic acquisitions like Retina Consultants of America. This growth underscores Cencora’s role in the healthcare supply chain and its focus on operational excellence, which is expected to continue driving resilient financial performance.
Spark’s Take on COR Stock
According to Spark, TipRanks’ AI Analyst, COR is a Outperform.
Cencora’s robust revenue growth and strategic acquisitions are significant strengths, offset by high leverage and recent cash flow challenges. While technical indicators show upward momentum, the stock’s high valuation remains a consideration.
To see Spark’s full report on COR stock, click here.
More about Cencora
Cencora, Inc. operates in the healthcare industry, focusing on pharmaceutical distribution and providing end-to-end services and solutions. The company aims to enhance its leadership position through a pharmaceutical-centric strategy and a customer-focused approach.
Average Trading Volume: 1,775,254
Technical Sentiment Signal: Buy
Current Market Cap: $56.39B
See more insights into COR stock on TipRanks’ Stock Analysis page.